Sun Pharma, the leading pharmaceutical company in India, has announced its plans to acquire Checkpoint Therapeutics for a significant sum of $355 million. This strategic move is aimed at bolstering Sun Pharma’s specialty portfolio, particularly with the addition of UNLOXCYT, an FDA-approved medication for advanced skin cancer. By acquiring Checkpoint Therapeutics, Sun Pharma is set to expand its global footprint in the field of oncology treatments. This acquisition highlights Sun Pharma’s commitment to growth and innovation in the pharmaceutical industry.